Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 2000; 100 (1): 57-70.
Green M.C., Murray J.L., Hortobagyi G.N. Monoclonal antibody therapy for solid tumors. Cancer Treat. Rev. 2000; 26 (4): 269-86.
Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480 (7378): 480-9.
Vannemann M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer. 2012; 12: 237-50.
Ciariello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Canc. Res. 2001; 7 (10): 2958-70.
Smyth M.J., Dunn G.P., Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 2006; 90: 1-50.
Zitvogel L., Tesniere A., Schreiber R.D., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006; 6 (10): 715-27.
Zou W. Immunosupressive networks in the tumor environment and their therapeutic relevance. Nat. Rev. Cancer. 2005; 5: 263-74.
Garrido F., Cabrera T., Lopez-Nevot M.A., Ruiz-Cabello F. HLA class I antigens in human tumors. Adv. Cancer Res. 1995; 67: 155-95.
Momburg F., Ziegler A., Harpprecht J., Moller P., Molden- Hauer G., Hammerling G.J. Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J. Immunol. 1989; 142: 352-8.
O’Flaherty E., Wong W.K., Pettit S.J., Seymour K., Ali S., Kirby J.A. Regulation of T-cell apoptosis: a mixed lymphocyte reaction model. Immunology. 2000; 100 (3): 289-99.
Kinder M., Chislock E., Bussard K.M., Shuman L, Mastro AM. Metastatic breast cancer induces an osteoblast inflammatory response. Exp. Cell Res. 2008; 324 (1): 173-83.
Wright-Browne V., McClain K., Talpaz M., Ordonez N., Estrov Z. Physiology and pathophysiology of dendritic cells. Hum. Pathol. 1997; 28: 563-79.
Shurin M.R., Shruin G., Lokshin A., Yurkovetsky Z.R., Gutkin D.W., Chatta G. et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Met. Rev. 2006; 25 (3): 333-56.
Zhang L., Yeger H., Das B., Irwinz M.S., Baruchel S. Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma. Neoplasia. 2007; 9 (1): 36-46.
Andersen M.H. The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase.Cancer Immunol. Immunother. 2012; 61: 1289-97.
Wesa A.K., Storkus W.J. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death. Different. 2008; 15: 51-7.
Jonson P., Glennie M. Rituximab: mechanisms and applications. Br. J. Cancer 2001; 85 (11): 1619-23.
Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer. 2001; 37 (4): 9-15.
Сакаева Д.Д., Гордиев М.Г. Рецептор эпидермального фактора роста как мишень молекулярно-направленной терапии у непредлеченных пациентов с немелкоклеточным раком легкого. Журнал «Злокачественные опухоли». 2016; 19 (3): 54-9
Abbruzzese J.L. Phase 2 study of anti-epidermal growth factor receptor (EGFR) antibody (IMC-C225), in combination with gemcitabine in patient with advanced pancreatic cancer. Ibid. 2001; 20: 518 (abstr).
Saltz Z., Rubin M. Cetuximab (IMC - C225) plus irinotecan (CPT - 11) is active in CPT-11 refractory colorectal cancer that express EGFR. Ibid. 2001; 20: 511 (abstr).
Hamilton A., Piccart M. The contribution of molecular markers to the prediction of response in the treatment of brest cancer: a review of the literature on Her-2, p53 and Bcl-2. Ann. Oncol. 2000; 11 (6): 647-63.
McKeage K., Perry C. Trastuzumab. A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002; 62 (1): 209-43.
Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L. et al: Efficacy and safety of Trastuzumab as a single agent in firstline treatment of HER2 overexpressing metastatic breast cancer (HER2+/MBC). J. Clin. Oncol. 2002; 3: 719-26.
Melnyk O., Zimmerman M., Kim K., Schuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J. Urol. 1999; 161: 960-3.
Neal D., Donovan J. Screening for prostate cancer. Ann. Oncol. 1998; 9: 12-7.
Bouzin C., Brouet A., De Vriese J., Dewever J., Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J. Immunol. 2007; 178 (3): 1505-11.
Huang Y., Chen X., Dikov M.M., Novitskiy S.V., Mosse C.A., Yang L., Carbone D.P. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood. 2007; 110 (2): 624-31.
Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab - VEGR. Drugs. 2002; 3 (1): 28-30.
Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R. et al. Randomized controlled trial of Yttrium-90-labelled Ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low grade, follicular or transformed B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 2002; 20 (10): 2453-63.
Chapman P.B., Hauschild A., Robert C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl. J. Medicine. 2011; 364 (26): 2507-16.
Menzies A.M., Long G.V., Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design Develop. Ther. 2012; 6: 391-405.
Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380 (9839): 358-65.
Haferkamp S., Borst A., Adam C., Becker T.M., Motschenbacher S., Windhovel S. et al. Vemurafenib induces senescence features in melanoma cells. J. Invest. Dermatol. 2013; 133: 1601-9.
Zhen L., Ke J., Xiaofang Zh., Guibin L., Fei S. Yongfu Zh. et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016; 370 (2): 332-44.
Novartis Pharmaceuticals, Study comparing combination of LGX818 plus MEK162 and LGX818 monotherapy versus vemurafenib in BRAF mutant melanoma (COLUMBUS). Clin. Trials. Gov. NCT01909453. 2015.
Lugowska I., Koseła-Paterczyk H., Kozak K., Rutkowski P. Trametinib: a MeK inhibitor for management of metastatic melanoma. OncoTarg. Ther. 2015; 8: 2251-9.
Larkin J., Ascierto P.A., Dréno B., Atkinson V., Liszkay G., Maio M. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 2014; 371 (20): 1867-76.
Pedoeem A., Azoulay-Alfaguter I., Strazza M., Silverman G.J., Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin. Immunol., 2014; 153 (1): 145-52.
Liang S.C., Latchman Y.E., Buhlmann J.E., Tomczak M.F., Horwitz B.H., Freeman G.J., Sharpe A.H. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 2003; 33 (10): 2706-16.
Chen D., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39 (1): 1-10.
Jurado J.O., Alvarez I.B., Pasquinelli V., Martínez G.J., Quiroga M.F., Abbate E. et al. Programmed death (PD)-1:PD-Ligand 1/PD-Ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J. Immunol. 2008; 181: 116-25.
Sharpe A.H., Wherry E.J., Ahmed R., Freeman G.J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunology. 2007; 8: 239-45.
Ishida M., Iwai Y., Tanaka Y., Okazaki T., Freeman G.J., Minato N., Honjo T. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 2002; 84 (1): 57-62.
Maine C.J. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Can. Immunol. Immunother. 2014; 63 (3): 215-24.
Mao Y., Li W., Chen K., Xie Y., Liu Q., Yao M. et al. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015; 6 (5): 3452-61.
Chen L., Zhang Z., Chen W., Zhang Z., Li Y., Shi M. et alB7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J. Immunol. 2007; 178: 6634-41.
Merelli B, Massi D, Cattaneo L, Mandala M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit. Rev. Oncol. Hematol. 2014; 89 (1): 140-65.
Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 2012; 12: 252-64.
Chen D., Irving B., Hodi F. Molecular pathways: next-generation immunotherap-inhibiting. Clin. Cancer Res. 2012; 18: 6580-7.
Hanahan D., Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011; 144 (5): 646-74.
Nelson D., Fiaher S., Robinson B. The “Trojan Horse” approach to tumor immunotherapy: targeting the tumor microenvironment. J. Immunol. Res. 2014; 15: 308.
Quesada S., Peggs K. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br. J. Cancer. 2013; 108: 1560-5.
Choueiri T.K., Fay A.P., Gray K.P., Callea M., Ho T.H., Albiges L. et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann. Oncol. 2014; 25 (11): 2178-84.
Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008; 26: 677-704.
Liu C., Peng W., Xu C., Lou Y., Zhang M., Wargo J.A. et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 2013; 19: 393-403.
Pollack B.P., Sapkota B., Cartee T.V. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin. Cancer Res. 2011; 17: 4400-13.
Soria J.C. Stahel A. PD-1 inhibitors raise survival in NSCLC. Cancer Discov. 2014; 4 (1): 6.
Maio M., Grob J.J., Aamdal S., Bondarenko I., Robert C., Thomas L. et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J. Clin. Oncol. 2015; 33 (10): 1191-6.
Нуриев Р.И., Караулов А.В., Киселевский М.В. Новые стратегии лечения пациентов с онкологическими заболеваниями: иммунотерапевтический подход. Иммунология. 2017; 38 (1): 39-48